Kazia Therapeutics Limited (KZIA) Earnings History
Net Loss27 years of earnings data (1999–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Kazia Therapeutics Limited (KZIA) Earnings Overview
As of June 13, 2026, Kazia Therapeutics Limited (KZIA) reported trailing twelve-month net income of -$47M, reflecting +65.6% year-over-year growth. The company earned $-30.37 per diluted share over the past four quarters, with a net profit margin of -49290.5%.
Looking at the long-term picture, KZIA's historical earnings data spans multiple years. The company achieved its highest annual net income of $1M in fiscal 2012.
Kazia Therapeutics Limited is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$158M net income, -297.1% margin), SNDX (-$243M net income, -165.6% margin), AGIO (-$423M net income, -764.0% margin), KZIA has room to improve margins relative to the peer group. Compare KZIA vs NKTR →
KZIA Earnings vs Peers
Earnings metrics vs comparable public companies
KZIA Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$21M | +22.7% | -$14M | $-18.90 | -49290.5% | -33850.0% |
| 2024 | -$27M | -30.8% | -$28M | $-55.00 | -1160.2% | -1233.2% |
| 2023 | -$20M | +18.2% | -$24M | $-55.00 | -3687419.8% | -4346661.1% |
| 2022 | -$25M | -197.1% | -$25M | $-95.00 | -250140.0% | -253990.0% |
| 2021 | -$8M | +32.5% | -$6M | $-35.80 | -55.5% | -42.0% |
| 2020 | -$12M | -21.4% | -$12M | $-80.00 | -1261.7% | -1234.3% |
| 2019 | -$10M | -70.1% | -$8M | $-85.60 | -656230.0% | -535463.3% |
| 2018 | -$6M | +43.4% | -$12M | $-59.80 | -46071.1% | -95262.4% |
| 2017 | -$11M | +11.5% | -$11M | $-109.30 | -121.4% | -123.5% |
| 2016 | -$12M | -69.0% | -$13M | $-135.20 | -296.3% | -313.7% |
| 2015 | -$7M | +4.4% | -$8M | $-143.45 | -8020.9% | -9147.2% |
| 2014 | -$7M | -624.4% | -$6M | $-226.25 | -8583.1% | -7357.5% |
| 2013 | -$1M | -178.8% | -$2M | $-42.70 | -96.6% | -191.0% |
| 2012 | $1M | +120.1% | -$10M | $64.15 | 53.4% | -395.1% |
| 2011 | -$6M | +47.4% | -$11M | $-302.15 | -320.9% | -564.9% |
| 2010 | -$12M | +34.8% | -$15M | $-574.05 | -124.6% | -153.7% |
| 2009 | -$19M | +6.5% | -$24M | $-883.50 | -169.8% | -213.3% |
| 2008 | -$20M | -1.2% | -$26M | $-985.45 | -152.6% | -194.6% |
| 2007 | -$20M | -23.3% | -$27M | $-973.60 | -115.5% | -156.0% |
| 2006 | -$16M | -32.7% | -$22M | $-792.65 | -120.1% | -165.2% |
| 2005 | -$12M | +2.2% | -$12M | $-599.80 | -69.5% | -69.1% |
| 2004 | -$13M | -20.1% | -$12M | $-617.75 | -76.5% | -75.8% |
| 2003 | -$10M | +29.0% | -$11M | $-542.45 | -31.6% | -31.9% |
| 2002 | -$15M | +65.6% | -$19M | $-767.80 | -74.8% | -97.0% |
| 2001 | -$43M | -211.8% | -$42M | $-2489.90 | -72.4% | -71.1% |
| 2000 | -$14M | +19.9% | -$14M | $-805.80 | -51.1% | -51.1% |
| 1999 | -$17M | - | -$18M | $-1498.00 | -88.4% | -93.8% |
Download Data
Export KZIA earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in KZIA back in 1999?
Total return with dividends reinvested · 27+ years of data
Calculate ReturnsHow much would $100/month in KZIA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs KZIA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationKZIA vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowKZIA — Frequently Asked Questions
Quick answers to the most common questions about buying KZIA stock.
What is KZIA earnings per share (EPS)?
KZIA trailing twelve-month (TTM) diluted EPS is $-30.37, reflecting +65.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1999 to 2025 is available in the table on this page.
What is Kazia Therapeutics Limited's net income?
Kazia Therapeutics Limited (KZIA) trailing twelve-month net income is $-47M as of 2025. Earnings grew +65.6% year-over-year.
Is KZIA profitable?
KZIA is not currently profitable on a TTM basis, reporting a net loss of $-47M. Net margin is -49290.5%. Investors should monitor for a return to profitability.
What is KZIA's earnings growth rate?
KZIA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1999 to 2025.
What are KZIA's profit margins?
Kazia Therapeutics Limited net profit margin is -49290.5%, operating margin is -33850.0%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is KZIA growing earnings?
Yes, KZIA earnings are accelerating — EPS growth of +65.6% exceeds the 5-year CAGR of N/A. TTM net income reached $-47M. Earnings momentum is strengthening.
What was KZIA's best earnings year?
Kazia Therapeutics Limited's highest annual net income on record is $1M, achieved in fiscal year 2012. Earnings history on this page spans 1999 to 2025 and includes all annual and quarterly figures.
What were KZIA's earnings last quarter?
KZIA's most recent reported quarter was Q4 2025. Net income was $-10M with diluted EPS of $-6.40. For a full breakdown of all quarters, see the quarterly earnings table on this page.